Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells

被引:0
|
作者
Jinno, H
Steiner, MG
Nason-Burchenal, K
Osborne, MP
Telang, NT
机构
[1] Cornell Univ, Coll Med, Dept Surg, New York, NY USA
[2] Cornell Univ, Coll Med, Dept Otolaryngol, Strang Canc Res Lab, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Med, Mol Med Lab, New York, NY 10021 USA
关键词
retinoid receptor; chemoprevention; breast cancer; HER-2/neu;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aberrant proliferation is an early-occurring event in vitro prior to tumorigenesis in vivo in the multistep process of carcinogenesis. Inhibition of aberrant proliferation therefore may represent a useful biomarker to evaluate the efficacy of chemopreventive agents. Retinoids have exhibited preventive efficacy in vitro and in vivo predominantly through the retinoic acid receptors (RARs) and the retinoid X receptors (RXRs). Clinically relevant biochemical and cellular mechanistic endpoints for chemopreventive effects of retinoids should provide novel biomarkers. The present study was designed to examine the preventive efficacy of natural retinoids, all-trans-retinoic acid (ATRA) and 9-cis-retinoic acid (9cisRA), and to identify the possible mechanisms for their effects using the HER-2/neu oncogene expressing preneoplastic human mammary epithelial 184-B5/HER cells. Seven-day treatment with ATRA and 9cisRA exhibited a dose-dependent growth inhibition. Long-term (21 days) treatment with IC20, doses of 50 nM ATRA and 100 nM 9cisRA inhibited anchorage-dependent colony forming efficiency by about 75.4% (p<0.01) and 84.9% (p<0.01), respectively. Cell cycle analysis revealed that a 24-h treatment with IC90 doses of 2 muM ATRA and 3 muM 9cisRA accumulates cells in the G(0)/G(1) phase and inhibit S and/or G(2)/M phase of the cell cycle. ATRA and 9cisRA induced an 11-fold p=0.03) and a 9-fold (p=0.04) increase in subG(0)/G(1) (apoptotic) population relative to the solvent control, respectively. ATRA and 9cisRA induced 77% (p=0.01) and 51% (p=0.02) decrease in tyrosine kinase immunoreactivity, respectively. Similarly, the two retinoids caused almost a 50% (p=0.01) down-regulation of Bcl-2 immunoreactivity. Western blot analysis revealed that ATRA induced an increase in RARbeta expression and a decrease in RARgamma expression, while 9cisRA down-regulated RXRalpha expression. These data demonstrate that ATRA and 9cisRA may inhibit HER-2/neu induced aberrant proliferation in part by retarding cell cycle progression, down-regulating HER-2/neu-mediated signal transduction and inducing Bcl-2-dependent apoptosis through a retinoid receptor-mediated mechanism.
引用
收藏
页码:127 / 134
页数:8
相关论文
共 50 条
  • [1] AMPLIFICATION OF HER-2/NEU ONCOGENE IN HUMAN OVARIAN-CANCER
    LEARY, JA
    EDWARDS, BG
    HOUGHTON, CRS
    KEFFORD, RF
    FRIEDLANDER, ML
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 1992, 2 (06) : 291 - 294
  • [2] Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein
    Sato, S
    Kajiyama, Y
    Sugano, M
    Iwanuma, Y
    Sonoue, H
    Matsumoto, T
    Sasai, K
    Tsurumaru, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 61 (01): : 203 - 211
  • [3] HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary
    Ross, JS
    Yang, F
    Kallakury, BVS
    Sheehan, CE
    Ambros, RA
    Muraca, PJ
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1999, 111 (03) : 311 - 316
  • [4] Antitumor efficacy of trastuzumab in nude mice orthotopically xenografted with human pancreatic tumor cells expressing low levels of HER-2/neu
    Pratesi, Graziella
    Petrangolini, Giovanna
    Tortoreto, Monica
    Addis, Alessandro
    Zunino, Franco
    Calcaterra, Claudia
    Merlo, Andrea
    Tagliabue, Elda
    Menard, Sylvie
    Balsari, Andrea
    JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) : 537 - 544
  • [5] Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system
    Croci, Stefania
    Recktenwald, Christian V.
    Lichtenfels, Rudolf
    Nicoletti, Giordano
    Dressler, Sven P.
    De Giovanni, Carla
    Astolfi, Annalisa
    Palladini, Arianna
    Shin-ya, Kazuo
    Landuzzi, Lorena
    Nanni, Patrizia
    Lollini, Pier-Luigi
    Seliger, Barbara
    PROTEOMICS, 2010, 10 (21) : 3835 - 3853
  • [6] Overexpression of HER-2/neu enhances the sensitivity of human bladder cancer cells to urinary isoflavones
    Su, SJ
    Lai, MD
    Yeh, TM
    Chow, NH
    EUROPEAN JOURNAL OF CANCER, 2001, 37 (11) : 1413 - 1418
  • [7] Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
    N Ady
    L Morat
    K Fizazi
    J-C Soria
    M-C Mathieu
    D Prapotnich
    L Sabatier
    L Chauveinc
    British Journal of Cancer, 2004, 90 : 443 - 448
  • [8] Detection of HER-2/neu-positive circulating epithelial cells in prostate cancer patients
    Ady, N
    Morat, L
    Fizazi, K
    Soria, JC
    Mathieu, MC
    Prapotnich, D
    Sabatier, L
    Chauveinc, L
    BRITISH JOURNAL OF CANCER, 2004, 90 (02) : 443 - 448
  • [9] Overexpression of HER-2/neu in Malignant Mammary Tumors; Translation of Clinicopathological Features from Dog to Human
    Muhammadnejad, Ahad
    Keyhani, Elahe
    Mortazavi, Pejman
    Behjati, Farkhondeh
    Haghdoost, Iraj Sohrabi
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (12) : 6415 - 6421
  • [10] Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells
    Subbarayan, Karthikeyan
    Leisz, Sandra
    Wickenhauser, Claudia
    Bethmann, Daniel
    Massa, Chiara
    Steven, Andre
    Seliger, Barbara
    ONCOIMMUNOLOGY, 2018, 7 (04):